Skin regeneration and anti-hyperkeratosis ointment with vitamin a

FIELD: medicine.

SUBSTANCE: invention concerns an ointment composition for reducing hyperkeratosis, softening, stimulating skin regeneration, containing retinol palmitate, α-tocopherol as a stabilising agent, as well as emulsion wax, Vaseline oil, glycerol, ethanol and water.

EFFECT: higher efficacy and stability.

2 dwg, 4 tbl, 4 ex

 

The invention relates to the pharmacy and for the creation of a topical composition for topical application, containing the retinoid is retinol palmitate with pharmacological effects on the proliferation and differentiation of keratinocytes, designed to soften the skin and enhance its regeneration, as well as for use in the treatment of skin diseases.

Biologically active forms of vitamin a are natural regulators of the morphogenetic processes in the epidermis [1]. In dermatological practice, it is frequently necessary to influence pathogenetic links of skin diseases by modifying the proliferation and differentiation of cellular elements of the epidermis and dermis. In recent decades this purpose are widely used synthetic analogs of vitamin a - retinoids, including retinol palmitate (RP) [2].

It is established that the TL through gene expression dose-dependently increases, while increasing the dose of vitamin a inhibits proliferation of keratinocytes. Known for its inhibitory effect on terminal differentiation of epithelial cells of the skin, which promotes rejuvenation of their population in the epidermis. Also RP activates the synthesis of glycosaminoglycans in the connective tissue layer of the skin, stimulates the immune processes.

Known p is apart Widestep ®representing ointment for cutaneous application, containing 0.5% RP based on the emulsion, stabilizers and antioxidants [3]. Its pharmacological activity in the form of impact on regenerative processes in the skin are proven in animal experiments [4] and confirmed in clinical practice [5, 6, 7]. The drug is effective in the treatment of eczema, dermatitis, heylita, surface cracks and abrasions of the skin, skin diseases associated with disturbances of its keratinization, is used for the activation of reparative processes in various dermatitis after treatment with glucocorticosteroids. It is approved for use by nursing mothers to eliminate cracked nipples [8].

In the patent literature there are reports of soft medicinal forms for cutaneous application, containing RP. Thus, patent RU 2115409 protects cosmetic product for skin care face and body, which consists of RP (vitamin a), tocopherol acetate (vitamin E), builders, plasticizing agents, preservatives, flavoring [9]. The wax composition described in patent RU 2146921 consists of SPM, ascorbyl palmitate, tocopherol acetate, ergocalciferol and water emulsion bases [10]. The above composition are multivitamin, vitamins, included in the composition as the active substances, first of all retinoid - RP, prone to oxidation, which, however, in the list of auxiliary substances, used in the compositions, stabilizers with antioxidant properties are missing.

The closest in purpose, composition and technical nature of the claimed invention is patent RU 2036640 describing the composition of the ointment compositions with RP, stabilized blend of antioxidants and containing emulsifier No. 1 [11]. It is known that to prevent oxidation of retinoids, including RP, typically used antioxidants equivalent (BOT) and butylhydroxyanisole (BOA) [12, 13]. These compounds are used in pharmacy and food industry, but found that they also have some undesirable effects, for example, the potential carcinogenic properties, the ability to raise cholesterol level [14, 15], to cause gastro-intestinal tract, liver, allergic reactions [16], to provide irritant effect on the skin, eyes and mucous membranes [17]. Part of the emulsifier composition No. 1 is a greasy feel a hard mass in the form of tiles weighing 10-15 kg; it requires the introduction into the production process stage "Grinding", coupled with the production losses and the use of expensive equipment.

Thus, in order to ensure the quality and improve the safety profile of the drug development of modern toksichnyh medicines for external use is important.

The present invention is the development of ointments, softening and healing the skin, preventing excessive keratinization and which has an improved safety profile.

In accordance with the invention describes a topical composition for external use, stimulating skin regeneration and prevent excessive keratinization and dryness of the skin, containing as active substance retinol palmitate, and as auxiliary substances α-tocopherol, emulsion wax, liquid paraffin, glycerin, ethyl alcohol and water in the following ratio, wt.%:

Retinol palmitate0,3-0,7
α-tocopherol0,15-0,25
The wax emulsion5,0-15,0
Vaseline oil5,0-15,0
Glycerin5,0-15,0
Ethanol 95%5,0-15,0
Distilled waterto 100.0

α-tocopherol (synthetic analogue of the natural α-tocopherol) is a non-toxic with the unity; as a stabilizer, it finds wide application in pharmaceutical and food industry. The use of α-tocopherol as an auxiliary substance for the purpose of preventing oxidation of the retinoid in the drug avoids the use of components such as BOT and BOA while maintaining a high pharmacological characteristics of the drug.

Emulsion wax unlike emulsifier No. 1 is a homogeneous mass in the form of flakes, easily weighed, mixed with vaseline oil, melts quickly and evenly, with no losses. Emulsion wax, obtained by fusing a synthetic primary fatty alcohols with potassium salts of esters of phosphoric acid, due to the presence of phosphate groups in the molecules of higher fatty acids similar in structure to the lecithin and cavalino within the sebum. As a consequence it has on the skin effective softening effect, prevents the loss of its moisture, does not leave a greasy feeling [18]. the pH of the emulsion obtained by the use of emulsified wax close to the natural value of this indicator in healthy skin.

Experiment 1

In the inventive composition of the ointment compositions of α-tocopherol introduced to stabilize retinoid, and therefore at the first stage of laboratory tests hundred is alnost RP was studied on the example of model mixtures.

Objective: to study the stability of the substance RP, stable α-tocopherol.

The object of the study amounted to model the mixture - a substance RP in vaseline oil without antioxidant (1) control and similar combination, characterized by the presence of the α-tocopherol (2). The initial concentration of SPM in model mixtures was 1%, the concentration of α-tocopherol is 0.05%. The samples were laid on "accelerated aging" in glass jars with a wide throat with free access of air at elevated temperatures (40°C).

Method: spectrophotometry towards the solution of the standard sample.

The results of the analysis of the concentration of SPM in model mixtures were stored at 40°C, are presented in table 1.

Table 1
The results of quantitative determination of retinol palmitate in model mixtures were stored at 40°C
No.The period of storage, daysThe quantitative content of retinol palmitate in model mixtures, %
without α-tocopherol (1)with α-tocopherol (2)
1 10,991,01
270,980,95
3220,980,99

4290,790,98
5360,490,95
6420,140,90
783-0,15

From these data it follows that the content of the SPM samples of both model compounds to 22-day observation remained almost at the same level. In further concentration of the substance in the sample, i.e. in the model mixture without antioxidant (1) began to decline. The analysis carried out in the following days, recorded a rapid decline in the concentration of retinoid in the control samples (figure 1). In the model mixture with an antioxidant (2) the concentration of retinoid save what was on the original level before the 36th day of observation, and only later was marked reduction (see table 1, Fig.1).

The obtained result shows that the presence in the model mixture of even minor amounts of α-tocopherol (0.05%) is almost twice prolongs the source resistance RP, which indicates the presence of α-tocopherol in the investigated conditions of strong antioxidant effect and, therefore, about the prospects of its introduction in the composition of medicines with the purpose of stabilizing retinoids.

Experiment 2

Objective: to establish an effective concentration of α-tocopherol, can slow down the oxidation RP for a long time.

The object of the study amounted to model the mixture - a substance RP in vaseline oil without antioxidant (1) and similar combinations (2-7), characterized in that in them was added α-tocopherol in different concentrations (table 2). The initial concentration of the retinoid in the model mixtures was 1%, α-tocopherol - 0,02-0,25%. The samples were laid on storage in glass jars with a wide throat with free access of air under more stringent than in the 1st experiment, the conditions of accelerated aging (50°C).

Method: spectrophotometry with respect to the standard sample.

Table 2
Sostavleniya mixtures with retinol-palmitate, stable α-tocopherol
No. mixture modelVaseline oil, %Retinol palmitate, %α-tocopherol, %
1to 99.001,00
298,981,00,02
398,951,00,05
498,891,00,11
598,871,00,13
698,811,00,19
798,751,00,25

The results of quantitative determination of SPM in model mixtures within 53 days of storage at 50°C are presented in figure 2.

The chart shows that different amounts of α-tocopherol in model mixtures have Nirav oznaczenie influence on the stability of the TL. The addition of an antioxidant in a concentration range from 0.02 to 0.05% when stored for 53 days at 50°C in the conditions of access of air proved to be ineffective. In the amount of 0.11% α-tocopherol stabilized retinoid, but not to the desired extent. Most high resistance RP in the studied conditions was observed at concentrations of α-tocopherol in model mixtures from 0.13 to 0.25% inclusive. I.e. the more a mixture of an antioxidant, the stronger until they reach a certain concentration) is its ability to prevent the oxidation/destruction of the pharmaceutical substance (RP)

Thus, experimental studies of the stability of the SPM during storage under conditions of accelerated aging in the composition of model mixtures containing α-tocopherol, has demonstrated the effectiveness of the selected approach to stabilization retinoid, i.e. replacement in the composition of a medicinal product of a mixture of antioxidants of phenol type (BOT and BOA) on synthetic analogue of the natural vitamin E, and allowed to proceed to the study of stability of SPM in the composition of the ointment compositions of the claimed composition.

Experiment 3

Purpose: to set the duration of stability of RP as a pharmaceutical substance in the composition of the ointment compositions containing α-tocopherol.

The object of the study was the sample ointment compositions, once ecaudata on the content of RP and α-tocopherol.

Method: high performance liquid chromatography.

Technology of preparation of ointment

1. The required amount of water is placed in the reactor 1 and heated to 75-80°C.

2. In parallel to the reactor 2 put the required quantity of paraffin oil and wax emulsion. The mixture is heated to a temperature of 75-80 C, melting components.

3. In the molten mixture in the reactor 2, weigh the calculated amount of RP and α-tocopherol. The mixture was mixed thoroughly with an immersion homogenizer.

4. In the reactor 1 (see claim 1) lower the cylinder homogenizer include it (8-10 thousand rpm) and with active stirring of the mixture into it slowly, in a thin stream, add the melt of drug substances and excipients ointment from the reactor 2.

5. After 2-5 minutes [depending on the volume of the reactor (0.5 to 3.0 l)] after mixing all components of the drug ointment homogenized.

6. After 2-5 minutes, the reactor was added a mixture of ethanol (ethyl alcohol) and glycerol (glycerin), then the ointment additionally homogenized for 2 minutes. Due to the fact that the ointment contains a thermolabile components (RP and α-tocopherol), the destruction of which is enhanced at high temperatures, it is forcibly cooled.

7. After reducing the temperature of the ointment to 35-40°C it is given to the packaging area in the tubes.

8. Ointment the FAS is t in aluminum tubes, mark labels and stored at a temperature of from 2 to 8°C.

Examples of the preparation of specific compositions

Example 4

1. In the reactor 1 with an effective load of 100 kg ointment measure 65,3 l of purified water, turn on the engine frame stirrer and heated water to a temperature of 75-80.

2. In the reactor 2 is weighed 8 kg of emulsion wax, 6 kg of paraffin oil, turn on the engine frame stirrer and heating the mixture to a temperature of 75-80°C, melt it.

3. After melting fatty components in the reactor 2 is weighed 0.5 kg RP and 0.2 kg of α-tocopherol and mix thoroughly.

4. The Association of the components of the ointment, in the reactor 1 and reactor 2, carried out with the active mixing using the built-in system of reactors rotary pulsation apparatus flow type.

5. Mixing the contents of two reactors continue for 20 minutes to obtain a homogeneous emulsion, which gradually add a mixture of 10 kg of ethyl alcohol and 10 kg of glycerin.

6. The resulting composition is finally homogenized for 15 minutes, cooled to a temperature of 30-35°C and Packed in aluminum tubes.

Similarly (same scheme) received other ointments (examples 1, 2, 3, 5 in tables 3 and 6, 7 in table 4).

Results

In the first stage, the antioxidant activity of different concentrations of α-tocopherol was studied on the example of mA is of evich compositions the content of the SPM which was 0.5%, i.e. the average of the declared values. Control served as the wax composition without stabilizer (table 3).

The study showed that in the control sample (example 1) and when using a 0.1%concentration of α-tocopherol (example 2) the content of SPM in the ointment compositions not withstand the required retention period (2 years). The increase in the concentration of antioxidant to 0.15% (example 3) and above (examples 4, 5) allowed to achieve the desired effect: the content of SPM in these experimental ointment compositions corresponded to the desired effect throughout the term corresponding to 3 years of storage under the conditions specified in the project to ND such ointments (2-8°C).

Table 3
The concentration of retinol palmitate in the ointment compositions stabilized α-tocopherol, in the determination of shelf life by the method of accelerated aging at 40°C
The experimental period of storage, daysShelf life, yearsThe content of retinol palmitate in ointments, %
Example 1Example 2the example 3 Example 4Example 5
without α-tocopherol0.1% of α-tocopherol0.15% of α-tocopherol0.2% of α-tocopherol0.25% of α-tocopherol
After manufacturing0,510,510,500,500,52
4610,490,520,500,510,50
691,50,480,510,510,500,51
9220,450,480,500,510,52
13830,400,450,49,51 0,50

Note: the quality indicators for ND from 0.45% to 0.55%.

In the second stage, the antioxidant activity of the minimum of the optimal effective concentrations of α-tocopherol (0,15%)established for the ointment 0.5%content of SPM, was studied on the example of the wax compositions, the content of the SPM which was 0.3%, 0.5% and 0.7%, which reflects the whole range claimed retinoid concentrations (table 4).

Table 4
The concentration of retinol palmitate in topical compositions containing 0.3%and 0.5% and 0.7%content of retinol palmitate, stable 0,15% α-tocopherol, when determining the shelf life by the method of accelerated aging at 40°C
The experimental period of storage, daysShelf life, yearsThe content of retinol palmitate in ointments, %
Example 6Example 3Example 7
0.3% RP0,5% RP0,7% RP
After manufacturing 0,520,71
4610,310,520,71
691,50,300,510,70
9220,310,510,68
1152,50,300,510,67

13830,310,500,67
Note: the quality indicators for ND from 0.27% to 0.33%, from 0.45% to 0.55% and 0.63 to 0,77%, respectively.

The study showed that the minimum of the optimal effective for ointment 0.5% SPM concentration of α-tocopherol exhibits the desired stabilizing effect in relation to topical compositions containing SPM within the stated concentration range, and ensures their stability within the SRO is the storage, under the project, ND.

Literature

1. Afanasiev SCI, Nozdrin V.I., Mikhailov, I. and other vitamin a - regulatory factor processes histogenesis // Successes of modern. Biol. - 1990. - so 6, No. 3. - S-418.

2. Guzev HP, Nozdrin V.I. New domestic medicinal products with retinoids): PNP "Retinoids", 2003. - 112 S.

3. Almanac "Retinoids". - M.: PNP "Retinoids", 2000. - VIP. - P.3-10.

4. Nozdrin V.I., yatskovskiy A.N., Guzev HP and other Experimental study specific pharmacological activity ointments Widestep // Almanac "Retinoids". - M.: PNP "Retinoids", 2000. - VIP. - C.11-16.

5. Ivanov Oleg Lundstrem, Samghin M.A., Panickin G.S. study of the efficacy and tolerability of the drug Vidistis (ointment with retinol-palmitate 0,5%) // the Almanac "Retinoids". - M.: PNP "Retinoids", 2000. - VIP. - Ñ.38-41.

6. Kubanova A.A., Fedorov, S.M., Timoshin, Clinical study ointments Vidistis (ointment with retinol-palmitate 0,5%) // the Almanac "Retinoids". - M.: PNP "Retinoids", 2000. - VIP. - P.42-44.

7. Basecoat YU. Clinical study of ointment Widestep containing 0.5% retinol palmitate // Almanac "Retinoids". - M.: PNP "Retinoids", 2000. - VIP. - P.46-48.

8. Albanova VI, Finger E.A. Application of ointments Widestep®in the lactation period // the Almanac "Retinoids". - M.: PNP "Retinoids", 2006. - VIP. - P.41-43.

9. Patent RU 2115409. - Publ. 20.07.1998.

10. Patent RU 2146921. - Published the. 27.03.2000.

11. Patent RU 2036640. - Publ. 10.06.1995.

12. Arhapchev P. definition butylacetate and butylacetyl in creams with retinol-palmitate by HPLC // Pharmaceutical science in addressing issues of drug supply. M., 1998. - Scientific proceedings. - So XXXVII. - Pp.86-89.

13. Guzev HP Theoretical justification and experimental study of dosage forms containing 13-CIS-retinoic acid and retinol palmitate: author. dis. Prof. the pharmacist Sciences. - M., 1997. - 50 S.

14. Inai, K., Kobuke T., Nambu, S. et al. Hepatocellular tumorigenicity of butilated hydroxytoluene administered orally to B6C3Fi mice // Jpn. J. Cancer Res. (Gann). - 1988. - Vol.79. - P. 49-58.

15. Kahl R., Kappus H. Toxicology of the synthetic antioxidants BHA and BHT in comparison with the natural antioxidant vitamin E // z fur Lebensmittel-Untersuchung und-Forchung. - 1993. - Bd. 196, N 4. - S. 329-338.

16. Serov Y.A. Dangerous food E-additives. Information and reference manual. - M., 2006. - 42 S.

17. The decision of the Customs Union Commission dated 19 may 2011, No. 646. About the project requirements for the labeling of drugs. - , Minsk.

18. Voitsekhovskaya A.L., Wolfenzon I.I. Chemistry for You. Cosmetics today. - M.: Chemistry, 1988. - S.

Topical composition for topical application, reducing the keratinization of the epidermis, softening the skin and stimulating her regenerative processes, on the basis of retinoid containing retinol palmitate, α-tocopherol, wax emulsion, oil, vaseline, glycerin, ethanol and water in the following with the respect of the components, wt.%:

Retinol palmitate0,3-0,7
α-tocopherol0,15-0,25
The wax emulsion5,0-15,0
Vaseline oil5,0-15,0
Glycerin5,0-15,0
Ethanol 95%5,0-15,0
Distilled waterto 100.0



 

Same patents:

FIELD: medicine, pharmaceutics.

SUBSTANCE: pharmaceutical oil-in-water emulsion contains mometasone or mometasone furoate, propylene glycol and water. The propylene glycol concentration makes from 20 to approximately 45 wt %. A mass ratio of propylene glycol and water in the oil-in-water emulsion makes from 1:1 to approximately 1:3. A portion of mometasone or mometasone furoate is found insoluble in the emulsion.

EFFECT: composition is characterised by stability and therapeutic effect.

27 cl, 6 dwg, 5 tbl, 4 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to field of pharmaceutics, in particular represents composition for topic application, which includes, into physiologically acceptable medium at least one derivative of naphthoic acid, benzoylperoxide and at least one film-forming component.

EFFECT: invention is characterised by the fact that said compound of naphthoic acid and benzoylperoxide are in dispersed in said composition form.

23 cl, 14 ex

FIELD: medicine.

SUBSTANCE: invention relates to a haemostatic anti-burn and wound-healing composition in the form of a hydrogel, which contains an active gel-forming component, a plasticiser, active and auxiliary components, namely a water-soluble heteropolymer of chitosonium salt in an amount from 1.0 to 10.0 wt %, a dexpanthenol substance and/or a 2-allyloxyethanol substance in an amount from 1.0 to 10.0 wt %, immobilised medicinal substances of aminocaproic or tranexamic acid in an amount from 0.1 to 5.0 wt % and calcium chloride in an amount from 0.05 to 2.0 wt %, immobilised medicinal substances of lidocaine or anylocaine in an amount from 0.1 to 5.0 wt % and chlorhexidine in an amount from 0.005 to 0.1 wt % and water.

EFFECT: extension of exploitation possibilities in stopping external capillary bleedings, local treatment of injured skin, non-healing wounds and local burns.

10 cl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine and describes a non-aqueous ointment containing a compound of vitamin D, corticosteroid and ester of N,N-di(C1-C8)alkylamino-substituted (C4-C18)alkyl(C2-C18)carboxylic acid in Vaseline, optionally containing mineral oil and tocopherol.

EFFECT: ointment is characterised by storage stability and high skin penetration of the corticosteroid.

23 cl, 4 dwg, 5 tbl, 3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to the pharmaceutical industry, namely to an ointment for burns, folliculitis, furunculosis, vasculitis treatment and wound healing. The ointment for burns, folliculitis, furunculosis, vasculitis treatment and wound healing containing: bees wax, line seed oil, kerosene and visceral fat of pig taken in certain proportions.

EFFECT: ointment possesses a biostimulating effect, reduces the wound healing time with no post-therapeutic cicatrisation with good fixation, uniform distribution on the skin surface and ease of use.

9 dwg, 9 ex

FIELD: medicine.

SUBSTANCE: invention relates to the application of a solid medicinal product, which is heated under the impact of an alternating magnetic field, for further therapeutic treatment after surgical ablation of tumours and cancerous ulcers. The medicinal product represents a surgical implant, presented in the form of a physiologically acceptable fabric, sponge or film. The medicinal product contains magnetic particles, which generate heat when excited by an impact of the alternating magnetic field, and in this way, heat the medicinal product.

EFFECT: invention ensures considerable improvement of further treatment after operation on cancerous tumour in comparison with chemotherapy.

21 cl, 14 ex

FIELD: veterinary medicine.

SUBSTANCE: method of preparing the anti-inflammatory veterinary ointment for outward application consists in mixing while heating to the temperature of 40-50°C in the reactor of molten petrolatum, pine oleoresin, chlorophyll-carotene paste until homogenous consistency, then glycerine and olive oil is fed portionwise with continuous stirring, after which again mixing of the components is carried out for 10-30 minutes until the homogeneous mass, the resulting ointment is cooled and packaged, at that the components of the mixture are taken in the following ratio, wt %: pine oleoresin 3.0; chlorophyll-carotene paste 3.0; petrolatum 69.0; glycerine 5.0; olive oil 20.0.

EFFECT: improved efficacy of treatment.

2 ex

FIELD: medicine.

SUBSTANCE: drug preparation for treating tuberculosis contains an active substance isoniaside, and a pharmaceutical carrier tiozol gel with the isoniaside concentration of 5.7-54.5 wt % and the tiozol gel concentration of 45.5-94.3 wt %.

EFFECT: higher clinical effectiveness in tuberculosis and lower toxicity.

2 cl, 2 tbl

Burn ointment // 2523551

FIELD: medicine.

SUBSTANCE: ointment contains biologically active substances which are Apis mellifera in an amount of 21-23 wt %, St. John's wort oil in an amount of 12-14 wt %, propolis in an amount of 10-12 wt % and wax in an amount of 7-9 wt %, as well as Vaselin and lanolin as the ointment base.

EFFECT: invention accelerates cell regeneration processes considerably due to a synergetic action of the ingredients.

7 ex

FIELD: medicine.

SUBSTANCE: pharmaceutical composition can additionally contain ethylenediaminotetraacetic acid, polyvinyl pyrrolidone, polyvinyl alcohol, a preserving agent specified in a group: Nipagin, Nipasol, benzoic acid, sodium benzoate, sorbic acid, benzalkonium chloride. As a body-forming base, the composition can contain distilled water, polyethylene oxide 400, polyethylene oxide 4000, polyethylene glycol, propylene glycol, a phosphate buffer, a borate buffer, an acetate-borate buffer depending on a dosage form.

EFFECT: high therapeutic effectiveness, prolonged corneal contact of the preparation which reduces the number of instillations, avoids a risk of side effects and provides good tolerance.

5 cl, 5 ex

FIELD: medicine.

SUBSTANCE: endodontic treatment stage involving retrieval and dilation of a root canal is performed. Gluftored liquid is introduced into the root canal of the tooth. A fibre cable is placed above a tooth canal orifice, and the liquid is reflected by means of a laser light for 30-60 seconds. The root canal is dried with a paper point. Pre-shaken Gluftored suspension is introduced into the root canal. The fibre cable is placed above the tooth canal orifice, and the suspension is reflected by means of the laser light for 30-60 seconds. The root canal is dried and filled.

EFFECT: method provides higher clinical effectiveness in the patients with dental pulp and periodontal diseases by activating the course of chemical reactions in mineralising liquid and suspension, crystal obturation of dentine tubes and closing a microbial invasion propagation path into the periodont to be protected against toxins and tissue disintegration products, forming a single mineral complex of the liquid, suspension and dentine of the root canal of the tooth, photobiostimulation of periodontal microcirculation by means of low intensity laser light energy, the presence of copper ions provides the permanent bactericidal effect.

10 dwg, 1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to a therapeutic agent for preventing and treating chronic liver diseases. The above agent represents amaranth oil prepared by cold pressing of amaranth seed kernels and coats, to be used in a dose of 62.5 - 250 mg/kg of body weight.

EFFECT: declared invention provides higher positive effect on biochemical processes in blood and liver tissues in treating toxic hepatitis.

2 tbl

FIELD: medicine.

SUBSTANCE: correcting the neurotoxic action of administering the preparation dapsone is ensured by using alpha tocopherol acetate as a correcting agent. Alpha tocopherol acetate is administered per os in a combination with dapsone to non-linear male and female white rats in a dose of 5 mg/kg once a day for 21 day.

EFFECT: using the method enables providing more effective correction of the neurotoxic side actions of dapsone with no side effects.

2 tbl

FIELD: veterinary medicine.

SUBSTANCE: aminoseleton is administered subcutaneously to animals in combination with symptomatic preparations - magestrofan, uteroton, tetragidrovit and etiotropic preparation. As etiotropic preparation the combination antimicrobial agent is used containing cefotaxime, neomycin, prednisolone, emulsifier, monoglyceride, vaseline oil, in the following ratio of components, wt %: cefotaxime - 7.0%, neomycin - 1.0%, prednisolone - 0.2%, emulsifier - 3.0%, monoglyceride - 1.0%, vaseline oil to 100.0, which is administered intrauterine 2-3 times with the 24-hour intervals in a dose of 20 ml.

EFFECT: invention improves therapeutic efficacy in chronic and latent endometritis.

3 tbl, 3 ex

FIELD: medicine.

SUBSTANCE: invention represents a drug preparation for treating diseases caused by type 1 herpes simplex and cytomegalovirus, containing recombinant human interferon 2α, lisocyme, Licopid, carnitine 20%, vitamin E and a fatty base.

EFFECT: higher clinical effectiveness and reduced length of treatment, prolonged intercurrent periods, lower recurrent rate by prophylactic administration, reduced manifestation of neurotoxic effects of herpes viruses, lower administration of antibiotics for preventing bacterial complications in infectious-inflammatory diseases caused by herpes simplex virus and cytomegalovirus in children.

2 cl, 3 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to the field of cosmetology, namely to a cosmetic composition for peroral introduction, which contains a combination of lycopene, vitamin C, vitamin E and at least one polyphenol compound, obtained from pine bark, in which the ratio of weight content of polyphenol compound to the sum of weight contents of lycopene, vitamin C and vitamin E constitutes from 0.3 to 0.7, as s single active ingredient.

EFFECT: invention is intended for prevention and/or treatment of wrinkles in the area of eyes and mouth angles, small wrinkles, eye bags and dark circles under eyes.

22 cl, 2 ex, 11 tbl

FIELD: medicine.

SUBSTANCE: there are used chymotrypsin 360-480 mg/day, trypsin 360-480 mg/day, papaine 900-1200 mg/day and 1,9-dihydro-9-beta-D-ribofuranosyl-6H-purin-6-one (Inosine) 1200-1800 mg/day, zinc 7-10 mg/day, selenium 50-100 mcg/day, vitamin E - 30-400 mg/day, C - 180-500 mg/day, B-carotin - 4-10 mg/day taken orally for 2-3 weeks during a female's follicular phase.

EFFECT: method enables reducing the binding of sperm-coating antibodies to sperm cells and improving the quantitative measures of the semen analysis through the complex immunomodulatory, proteolytic, inflammatory, antioxidant, antihypoxic and anabolic effects.

1 ex, 1 tbl

FIELD: agriculture.

SUBSTANCE: invention relates to biotechnology and can be used to increase the productivity of broiler chickens. The method comprises feeding the combined fodder with feed additive comprising selenium with the particle size of 20-60 nm, solubiliser Solutol HS 15 of vitamin E and water in a predetermined ratio, which is administered together with drinking water continuously during 15 to 42 days of broiler fattening at a dose of 0.125 wt.% of selenium and 3.8 wt.% of vitamin E per litre of drinking water. At that the feed additive is an aqueous solution of stabilised selenium particles with size of 20-60 nm, vitamin E and solubiliser Solutol HS 15.

EFFECT: invention enables to normalise metabolic processes, the activate the body's antioxidant defence systems, to increase the feed conversion rate and to increase the live weight gain.

2 tbl, 1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutics, and aims at the prevention and treatment of hypovitaminosis and the normalisation of metabolism. The drug preparation contains vitamin A, vitamin D3, vitamin E, vitamin C; a selenium compound is presented by DAFS-25 in the following ratio of the ingredients in 1 l of the solution: vitamin A - 25.0-35.0 ml, vitamin D3 - 0.03-0.05 ml, vitamin E - 55.0-65.0 g, vitamin C - 90.0-110.0 g, DAFS-25 - 0.2-0.4 g, polysorbate-80 - 190.0-210.0 ml, 2-pyrrolidone 39.0-41.0 ml, distilled water - up to one litre.

EFFECT: using the declared invention enables increasing the immune status in poultry, normalising the antioxidant and detoxifying systems, improving the livability, egg production and meat production along with reducing the feed consumption per a unit of product.

3 tbl, 3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical industry, namely to a composition for reducing oxidative stress in the skin caused by sunlight or ultraviolet light. A chewable composition for reducing oxidative stress caused by sunlight or ultraviolet light (UVB) in the skin, containing vitamin C, vitamin E, green tea extract having the content of epigallocatechin (EGC) of at least 20%, and gallic acid in a certain amount. A method for preserving an individual's healthy skin in the oxidative process caused by sunlight or ultraviolet light involving the oral administration of the composition.

EFFECT: composition is effective for reducing oxidative stress in the skin caused by sunlight or ultraviolet light.

14 cl, 6 tbl, 4 ex

FIELD: veterinary medicine.

SUBSTANCE: aminoseleton is administered subcutaneously to animals in combination with symptomatic preparations - magestrofan, uteroton, tetragidrovit and etiotropic preparation. As etiotropic preparation the combination antimicrobial agent is used containing cefotaxime, neomycin, prednisolone, emulsifier, monoglyceride, vaseline oil, in the following ratio of components, wt %: cefotaxime - 7.0%, neomycin - 1.0%, prednisolone - 0.2%, emulsifier - 3.0%, monoglyceride - 1.0%, vaseline oil to 100.0, which is administered intrauterine 2-3 times with the 24-hour intervals in a dose of 20 ml.

EFFECT: invention improves therapeutic efficacy in chronic and latent endometritis.

3 tbl, 3 ex

Up!